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Abstract
Background: Epithin/PRSS14, a type II transmembrane serine protease, is an emerging target of cancer therapy
because of its critical roles in tumor progression and metastasis. In many circumstances, the protease, through its
ectodomain shedding, exists as a soluble form and performs its proteolytic functions in extracellular environments
increasing cellular invasiveness. The seemingly functional integrity of the soluble form raises the question of why
the protease is initially made as a membrane-associated protein.
Results: In this report, we show that the epithin/PRSS14 intracellular domain (EICD) can be released from the
membrane by the action of signal peptide peptidase-like 2b (SPPL2b) after ectodomain shedding. The EICD
preferentially localizes in the nucleus and can enhance migration, invasion, and metastasis of epithelial cancer when
heterologously expressed. Unbiased RNA-seq analysis and subsequent antibody arrays showed that EICD could
control the gene expression of chemokines involved in cell motility, by increasing their promoter activities. Finally,
bioinformatics analysis provided evidence for the clinical significance of the intramembrane proteolysis of epithin/
PRSS14 by revealing that the poor survival of estrogen receptor (ER)-negative breast cancer patients with high
epithin/PRSS14 expression is further worsened by high levels of SPPL2b.
Conclusions: These results show that ectodomain shedding of epithin/PRSS14 can initiate a unique and
synchronized bidirectional signal for cancer metastasis: extracellularly broadening proteolytic modification of the
surrounding environment and intracellularly reprogramming the transcriptome for metastatic conversion. Clinically,
this study also suggests that the intracellular function of epithin/PRSS14 should be considered for targeting this
protease for anti-cancer treatment.
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Background
Protease serine 14 (PRSS14), a gene of the 14th serine pro-
tease, was initially named as epithin [1] and is also known
as Matriptase [2], MT-SP1 [3], or ST14 [4]. It is a proto-
typic member of type II transmembrane serine protease
containing its relatively short cytoplasmic tail in the N-
terminal and its extracellular protease part in the C-
terminal regions [5, 6]. Many studies have shown that
epithin/PRSS14 is upregulated in a variety of human epi-
thelial cancers [7] and is tightly linked to higher tumor
grades and poorer survival of patients [8–11]. Recently, we
reported from the analysis of public databases of patients
with breast cancer that epithin/PRSS14 is a prominent
prognosis marker for patients with estrogen receptor
(ER)-negative breast cancer [12]. The role of epithin/
PRSS14 in metastasis and survival has been evaluated in
multiple animal studies. Impaired metastasis was observed
when cancer cells with low epithin/PRSS14 expression
were injected [13]. In contrast, the high expression of
epithin/PRSS14 enhanced angiogenesis, invasive tumor
growth, and metastasis [14, 15]. Transgenic mice express-
ing epithin/PRSS14 driven by the K5 promoter developed
spontaneous squamous carcinoma and metastasis [16].
When MMTV-PyMT mouse models were crossed with a
matriptase hypomorphic model, expressing very little
epithin/PRSS14 expression, the animals lived longer with
less tumor burden [17]. These studies clearly show the im-
portant role of epithin/PRSS14 in tumor progression, thus
making it a promising target for anti-cancer therapy [6].
Our previous study showed that epithin/PRSS14 is syn-
thesized as a single-chain zymogen and is cleaved between
Gly149 and Ser150 in the SEA (sperm protein, enteroki-
nase, and agrin) domain to produce two fragments, the N-
terminal fragment (NTF) and the C-terminal ectodomain
containing the protease domain (named as Epi-S), which
are non-covalently associated on the membrane [18]. The
cleavage in the SEA domain is suggested to be mediated
by self-cleavage mechanism through attack of the hydroxyl
group of the serine residue on the neighboring glycine car-
bonyl group, without involvement of action of other pro-
teases [19]. Further cleavage at Arg186, Lys189, or Lys204
releases most of the ectodomain, leaving the NTF and the
small ectodomain fragment on the plasma membrane.
This shedding is initiated by various stimuli, such as the
serum [20], phorbol 12-myristate 13-acetate (PMA) [21],
transforming growth factor-β (TGF-β) [22], hypoxia [23],
and acidic conditions [24], which possibly activates its
sheddases, TACE/ADAM17 [22, 25] and/or serine prote-
ase [24]. Consistently, we have shown that knocking down
TACE inhibits the ectodomain shedding of epithin/
PRSS14 [22, 25]. The released extracellular domain may
extend the proteolytic effects of epithin/PRSS14 to a larger
degree modulating the extracellular microenvironment in
favor of cellular invasion. If this is the case, why the
protease is made as an integral membrane protein and has
to be released by an additional step is of question. In this
regard, the possible role of NTF of epithin/PRSS14 was
investigated.
Here, the intracellular function of NTF is presented. Spe-
cifically, it was found that NTF of epithin/PRSS14 left on
the plasma membrane upon ectodomain shedding can be
further processed and liberated from the membrane by
intramembrane proteolysis. It was also found that the
epithin/PRSS14 intracellular domain (EICD) can promote
migration, invasion, and cancer metastasis, possibly through
transcriptional changes. The intracellular function of the
protease would be locked until ectodomain shedding oc-
curs, and when unlocked, it can potentiate cellular behav-
iors mediated by the released extracellular protease.
Therefore, we suggest that its existence as an integral mem-
brane protein may be required for the cooperative functions
of extracellular and intracellular domains in a synchronized
manner at the time of ectodomain shedding.
Results
The intracellular domain of epithin/PRSS14 is detected in
the nucleus
When 427.1.86 thymoma cells (427 cells) expressing
epithin/PRSS14 endogenously were stained with an anti-
body generated against the ectodomain of epithin/PRSS14
(anti-C), a membrane staining pattern was observed pref-
erentially in the cell-cell contacts (Fig. 1a). However, when
stained with an antibody against the intracellular domain
(anti-N), a punctate staining pattern in the nucleus was
also observed (Fig. 1a). These staining patterns were not
observed in the 427(epiKD) cells (Fig. 1a), a cloned cell
line derived from epithin/PRSS14 targeting shRNA-
transfected 427 cells (Fig. 1b), showing specificities of the
staining. In addition, the intracellular domain tagged with
the FLAG epitope was also localized in the nucleus (Fig.
1c). These findings raise the possibility that the epithin/
PRSS14 N-terminal region may detach from the plasma
membrane and translocate to the nucleus.
To test this, the epithin/PRSS14-GAL4-VP16 construct
(Epi-GV) was generated in which the GAL4-VP16 is
inserted into the cytoplasmic tail of the protease (Fig. 1d)
and whether it can induce transcription of the luciferase
gene under a GAL4 upstream activating sequence (GAL4-
UAS-luciferase) was examined. Surface expression of the
GAL4-VP16-inserted epithin/PRSS14 construct was con-
firmed by flow cytometry (Additional file 1: Figure S1A
and S1B). Since transcription of the luciferase gene is only
possible when the GAL4-VP16 can freely move to the nu-
cleus, this system allows sensitive detection of a possible
liberation of the cytoplasmic tail of membrane proteins
[26]. As a control, the intracellular domain part of epithin/
PRSS14 was fused to GAL4-VP16, Epi (1-44)-GV, which
can mimic a liberated intracellular domain of the fusion
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protein. When co-transfected with GAL4-UAS-luciferase
reporter into 427 cells, EICD-GV largely induced lucifer-
ase activity in all conditions (Fig. 1e). In contrast, 427 cells
transfected with Epi-GV showed increases in luciferase ac-
tivity only when its ectodomain shedding was induced by
treating serum or PMA (Fig. 1e). Moreover, the PMA-
induced increase in luciferase activity was blocked by
treating a known epithin/PRSS14 shedding inhibitor, eco-
tin [21]. Consistently, when serum-starved 427 cells were
stimulated with PMA, the nuclear dots recognized by
anti-N antibody were increased, while knocking down the
epithin/PRSS14 expression by siRNAs suppressed the in-
crease (Additional file 1: Figure S2A). Quantification ana-
lysis using an in-house Matlab code (Additional file 1:
Fig. 1 Nuclear localization of epithin/PRSS14 intracellular domain. a Epithin/PRSS14 in 427.1.86 cells (427) or epithin/PRSS14-knockdown
427(epiKD) cells were stained green using antibodies against its extracellular C-terminal parts (anti-C) and intracellular parts (anti-N). Nucleus
staining with DAPI (blue) is also shown. Scale bars, 20 μm. b The Western blot analyses of epithin/PRSS14 in 427 cells and 427 (epiKD) cells are
shown. c The 427 cells transfected with FLAG-EICD were stained using anti-FLAG antibody (green) and DAPI (blue). Scale bars, 10 μm. d
Schematic diagram of the assay to validate cleavage of epithin/PRSS14. e The 427 cells were transfected as indicated and deprived of serum
before stimulation with 10% FBS, 10 μM PMA, or 10 μM PMA plus 7 mg/ml ecotin for 1 h. Luciferase activity under each condition was normalized
against β-galactosidase (β-gal) activity and is shown as a bar graph. Error bars indicate the standard errors of the means (n = 3)
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Figure S2B and S2C) confirmed significant increase of the
nuclear dots in PMA-treated condition (Additional file 1:
Figure S2D). Together, these results show that ectodomain
shedding of epithin/PRSS14 can liberate EICD from the
membrane.
Ectodomain shedding of epithin/PRSS14 generates EICD
To verify the existence of the EICD, the proteolytic frag-
ments of epithin/PRSS14 in 427 cells were analyzed using
various antibodies (Fig. 2a). As reported previously, about
5% of Epi-S in cells was shed and detected in media as
Epi-S' upon PMA treatment (Fig. 2b, top panel). Immuno-
precipitation and subsequent Western blot using the anti-
N antibody detected the NTF (Fig. 2b). After more pro-
longed exposure of the same membrane, a smaller frag-
ment was also detected with a molecular weight (~ 14
kDa) corresponding to the size of EICD in the immuno-
precipitates from PMA-treated cells (Fig. 2b, bottom
panel). The 14 kDa band disappeared by adding the anti-
gen of anti-N antibody (Gly12-Arg25) to the immunopre-
cipitation reaction (Fig. 2c) and also by siRNA-mediated
knocking down epithin/PRSS14 expression (Additional file
1: Figure S3A), confirming that the band was derived from
epithin/PRSS14. Moreover, the 14 kDa band was preferen-
tially observed in the nuclear fraction, but not in cytosolic
fraction, of PMA-stimulated cells, while knocking down
epithin/PRSS14 expression reduced the band intensity in
the nuclear fraction again (Additional file 1: Figure S3B).
In MCF7 human breast cancer cells known to express
epithin/PRSS14, similar ~ 14 kDa proteolytic fragment
was observed using the anti-N antibody raised against the
human epithin/PRSS14 intracellular domain (Fig. 2d), in-
dicating that the generation of the EICD may be the gen-
eral phenomena in epithin/PRSS14-expressing cells. In
agreement with the result from the GAL4-VP16 transcrip-
tional system (Fig. 1e), the inhibition of shedding by the
TACE inhibitor TAPI-0 reduced the EICD generation
(Fig. 2e). Taken together, these data suggest that the ecto-
domain shedding of epithin/PRSS14 generates EICD.
SPPL2b is responsible for the intramembrane proteolysis
of epithin/PRSS14
These observations led to the hypothesis that EICD may
be generated by the proteolytic cleavage occurring inside
the membrane, known as regulated intramembrane prote-
olysis (RIP) [27]. Because the aspartyl protease SPPL fam-
ily is responsible for the RIP of type II transmembrane
proteins [28], the possible involvement of SPPLs in the
production of EICD was investigated. First, treatment of
an inhibitor of the SPPL family, (Z-LL)2ketone, reduced
the PMA-induced increase in EICD formation (Fig. 3a). In
contrast, DAPT, an inhibitor of γ-secretase responsible for
the RIP of type I transmembrane protein, had no effect on
the generation of EICD (Additional file 1: Figure S4).
Second, expression of SPPL2b, the only member of an
SPPL family known to be present in the plasma mem-
brane [29], in HEK293T cells resulted in the generation of
EICD from co-transfected epithin/PRSS14 in a dose-
dependent manner (Fig. 3b and c). Third, in SPPL2b
known-downed 427 cell lines, 427(SP2bKD)-10 and -16
(Fig. 3d), PMA-induced EICD generation decreased (Fig.
3e, bottom panel and 3F), while PMA-induced shedding
occurred normally (Fig. 3e, top panel). Finally, the nuclear
staining of epithin/PRSS14 was also diminished in
427(SP2bKD)-10 cells without alteration to membrane
staining at the cell-cell contact (Fig. 3g and Additional
file 1: Figure S5A). Consistently, the EICD band in the nu-
clear fraction observed in PMA-treated 427 cells was
largely reduced in 427(SP2bKD) cells (Additional file 1:
Figure S5B). Collectively, these results showed that
SPPL2b may be an enzyme responsible for the cleavage of
NTF left on the plasma membrane and the production of
EICD. Nonetheless, we do not exclude a possible contri-
bution of other member of SPPL family, e.g., SPPL2a, on
the EICD production.
EICD promotes cell migration, invasion, and metastasis
To establish the existence of EICD, the consequences of its
liberation from the membrane were investigated. To this
end, 427(SP2bKD) cells were utilized in which shedding-
dependent EICD formation is impaired (Fig. 3e). When the
ectodomain shedding of epithin/PRSS14 was induced by
PMA treatment, 427 cells showed a significant increase in
wound healing migration compared to the untreated con-
trol (Fig. 4a). PMA treatment also significantly increased
the invasion of cells through Matrigel-coated pores of the
transwell chamber (Fig. 4b). Knocking down epithin/
PRSS14 significantly reduced the PMA-induced migration
and invasion (Additional file 1: Figure S6A and S6B). Im-
portantly, the PMA-induced increases in migration and in-
vasion were also largely reduced in 427(SP2bKD) cells (Fig.
4a and b). Moreover, transfection of EICD in the SP2bKD-
10 cells rescued the impaired wound healing migration and
invasion caused by SPPL2b deficiency (Additional file 1:
Figure S6C and S6D). These results suggest that EICD for-
mation from the ectodomain shedding of epithin/PRSS14
may promote cell motility. To directly test the effect of
EICD on cell motility, an EICD construct was stably trans-
fected into 427 cells to establish 427(EICD)-1 and -5 cell
lines. While the original 427 cells exhibited the epithelial
phenotype characterized by well-developed cell-cell con-
tacts forming cohesive sheets of cells, these EICD-
expressing cell lines showed loosened cell-cell adhesion
and more scattered morphology (Fig. 4c), suggesting that
EICD can enhance the motility of the cells. Indeed, migra-
tion rates of EICD-expressing cells, compared to the ori-
ginal cells, were significantly increased in the wound
healing assay (Fig. 4d) as well as in the Matrigel-coated
Cho et al. BMC Biology           (2020) 18:60 Page 4 of 16
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Fig. 2 Ectodomain shedding induced the generation of the epithin/PRSS14 intracellular domain. a Schematic diagram of the epithin/PRSS14
domain structure, its possible proteolytic fragments, and epitopes of antibodies used in this study are illustrated. TM, transmembrane domain;
SEA, sperm protein, enterokinase, and agrin domain; CUB1, CUB2, complement subcomponent C1r/C1s domain; 1, 2, 3, 4, low-density lipoprotein
receptor class A repeats. b The 427 cells were treated with or without PMA and shed epithin/PRSS14 (Epi-S′) was analyzed using mAb5. Cell-
bound epithin/PRSS14 (Epi-S), NTF, and EICD were detected by immunoprecipitation and subsequent Western blot with mAb5 and anti-N
antibody under each condition. CS, control serum. c After the antigen of anti-N antibody (Gly12-Arg25) was added or left out of the
immunoprecipitation reaction, Epi-S, NTF, and EICD in the anti-N antibody, immunoprecipitates were analyzed as in b. d The proteolytic fragment
of human epithin/PRSS14 was analyzed using MCF7 human breast cancer cells. e The 427 cells were treated with PMA and/or TAPI-0, and each
fragment was analyzed as in b. Arrowhead and arrow indicate NTF and EICD, respectively
Fig. 3 SPPL2b-mediated intramembrane proteolysis of epithin/PRSS14. a The 427 cells were treated with PMA and/or SPPLs inhibitor, 10 μM (Z-
LL)2ketone and proteolytic fragments were analyzed as in Fig. 2b. b HEK293T cells transfected with FLAG-tagged epithin/PRSS14 and increasing
amounts of SPPL2b-HA were analyzed by Western blot using the anti-FLAG antibody to detect NTF and EICD. The expression of SPPL2b and full-
length epithin/PRSS14 were also confirmed by Western blot using anti-HA and anti-FLAG antibodies, respectively. Asterisk indicates
uncharacterized fragments, presumably resulted from nonspecific cleavages, glycosylation, and/or other modifications of overexpressed epithin/
PRSS14. c EICD band intensity was quantified and normalized against tubulin blot and is shown as a bar graph (n = 3). The error bar indicates SD.
*p < 0.05, **p < 0.01 (unpaired two-tailed Student’s t test). d The mRNA levels of SPPL2b in SPPL2b-knockdown cell lines (SP2bKD-10 and -16)
were detected by real time-PCR. The relative values were normalized to GAPDH signals, as shown in the graphs. Error bars indicate SEM. e
Proteolytic fragments of epithin/PRSS14 were analyzed in the control and SP2bKD cells, as in Fig. 2b. f The average of normalized EICD band
intensities from three independent immunoprecipitation experiments is shown as a bar graph (n = 3). The error bar indicates SD. *p < 0.05
(unpaired two-tailed Student’s t test). Arrowhead and arrow indicate NTF and EICD, respectively. g Localization of the N-terminal and C-terminal
parts of epithin/PRSS14 were analyzed, as in Fig. 1a. Note that the nuclear localization of EICD (arrows) was reduced in SP2bKD-10 cells
(arrowheads). Scale bars, 20 μm
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transwell invasion assay (Fig. 4e). These results prompted
the assumption that the well-known enhanced metastatic
phenotype of epithin/PRSS14 expressing cancer cells may
be caused, at least in part, by the EICD production in the
cells. To verify this, epithin/PRSS14 targeting shRNA was
stably transfected into 4T1 cells (4T1KD cells), mouse
breast cancer cells derived from the BALB/c strain [30],
and the cells were transduced with lentivirus encoding
EICD followed by the internal ribosome entry site and GFP
reporter. The resulting 4T1KD/EICD:GFP cells were
injected into BALB/c mice, and the metastatic nodule for-
mation in the lungs was investigated. Comparison of tumor
nodule formation between individual mice may cause pos-
sible artifacts resulting from the difference in the number
of cells injected or in the metastatic susceptibility of indi-
vidual mice. In order to minimize possible artifacts, these
4T1KD/EICD:GFP cells were mixed with parental control
4T1KD cells in a fixed ratio before injection and the in-
crease in the ratio of EICD-positive tumor nodules to con-
trol nodules was analyzed (Diagram, Fig. 4f). In this
analysis, EICD-positive cells set as ~ 25% of total cells, veri-
fied by flow cytometry before injection (Fig. 4g), made up
to about 75% of tumor nodules in the lung (Fig. 4h-i) when
the expression of GFP in each nodule was analyzed by
Western blot (Additional file 1: Figure S7).
Altogether, these results suggest that EICD liberated
from the membrane after the ectodomain shedding of
epithin/PRSS14 can promote metastatic conversion
within the cells.
EICD induces changes in gene expression
Next, the molecular basis of the EICD-mediated increase in
cell motility was assessed. Because EICD is found in the nu-
cleus, it was hypothesized that EICD might contain tran-
scription activity as is often observed in other RIP
substrates [27]. First, to test this hypothesis, RNA-seq ana-
lysis was performed, and the determination of possible gen-
etic changes induced by EICD was attempted. For this
purpose, 427(SP2bKD)-10 cells were transfected with either
GFP or GFP plus EICD, RNA was prepared from GFP-
positive cells, and differentially expressed genes (DEGs)
were analyzed between samples. A total of 233 DEGs with
more than a twofold increase in EICD-transfected cells
were identified (Fig. 5a, red dots) among significant DEGs
(p value < 0.05, Additional file 2: Table S1). In the gene
ontology (GO) analysis using these 233 genes, migration-
related GO terms were dominant (Additional file 1: Figure
S8), which is consistent with the role of EICD in cell motil-
ity. Notably, several chemokine ligands (CCL3, CCL20, and
CXCL2), widely studied as mediators of epithelial-
mesenchymal transition, tumorigenesis, and metastasis
[31–35], were increased (Fig. 5a) and top-ranked in terms
of the fold increase (Additional file 2: Table S1). To confirm
the effect of EICD on the increase in cytokine mRNA ex-
pression, the levels of various cytokines secreted from
EICD-expressing SP2bKD cells were checked using a cyto-
kine antibody array (Fig. 5b and Additional file 1: Figure
S9). Among the total 111 cytokines tested in the array, the
secretion of 26 proteins, such as CCL20 and CXCL2, in-
creased by up to 1.2-fold by EICD expression (Fig. 5c).
Among those 26 proteins, the mRNA expression of nine se-
creted proteins (Fig. 5c, labeled with red fonts) significantly
increased in the RNA-seq analysis (Additional file 2: Table
S1). This gene expression increase does not appear to result
from EICD’s transactivation activity because EICD fused to
the Gal4 DNA binding domain did not induce transcription
of the UAS-GFP reporter (Fig. 5d) as has been similarly ob-
served in other RIP products, e.g., amyloid precursor pro-
tein [36]. Instead, when about 1 kb long promoter region of
CCL20, of which expression was increased in both the
RNA seq analysis and cytokine array, was inserted up-
stream of the GFP reporter, it was observed that EICD
could significantly induce GFP expression (Fig. 5e), suggest-
ing its possible function in activating machinery involved in
the transcription of the CCL20 gene. Altogether, these re-
sults showed that EICD liberated from the ectodomain
shedding of epithin/PRSS14 can regulate gene expression,
especially of cytokines, and modulate surrounding microen-
vironments favoring cell motility.
(See figure on previous page.)
Fig. 4 Effects of the intracellular domain of epithin/PRSS14. a The wound healing migration of 427, 427(SP2bKD)-10, and -16 cells in PMA-
stimulated or non-stimulated conditions was analyzed. Data are presented as the means of the recovered area (six fields per each cell type, n =
3). b Invasion of 427, 427(SP2bKD)-10 and -16 cells in the presence or absence of PMA was analyzed. Numbers of migrated cells to the other side
of the chamber for 24 h were counted, normalized against that of 427 cells, and shown as fold changes (n = 3). c Representative bright-field
images of 427, 427(EICD)-1, and -5 cells are shown. The percentage of scattered cells over the total number of cells (> 745 cells in 50 fields) in
each cell type is represented as a bar graph. Scale bars, 50 μm. d The degrees of migration of 427, 427(EICD)-1, and -5 for 24 h in the wound
healing assay are quantified (six fields per each cell type, n = 3) and shown as bar graphs. e Invasion of 427, 427(EICD)-1, and -5 cells through
transwell pores covered with Matrigel were analyzed as in b (5 fields per each cell type, n = 3). Statistical analysis was performed using an
unpaired two-tailed Student’s t test. f A diagram of the lung metastasis assay is depicted. g The GFP fluorescence of 4T1KD plus EICD-transduced
4T1KD cells (4T1KD/EICD:GFP) was analyzed by flow cytometry and is shown as a histogram. h Representative lungs from mice injected with PBS
(left) or 4T1KD/EICD:GFP cells (middle, right) are shown. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Error bars indicate SEM in all panels. i
The percentage of GFP-positive cells in the mixed cells before injection and the GFP-positive nodules in five lungs after injection are shown. Error
bars indicate SD
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Fig. 5 EICD-induced gene expression. a DEG analysis was performed between RNA samples from GFP- and GFP plus EICD-transfected cells. The
results were visualized as MA plots in which log2 fold change (y-axis) and mean of normalized counts (x-axis) from FPKM (fragments per kilobase
million) values are plotted. Genes with p values less than 0.05 are shown as red dots. Representative genes are indicated with arrows. b Specific
antibodies against various cytokines (Additional file 1: Figure S3) were spotted onto the array in duplicate. Conditioned media from SP2bKD-10
cells (SP2bKD, upper) and EICD-expressing SP2bKD-10 cells (SP2bKD/EICD, lower) were incubated on the antibody array. Spots with more than
1.2-fold increases in media from SP2bKD/EICD cells are boxed in red. Positions of representative cytokines were indicated with arrows. c Cytokines
showing more than a 1.2-fold increase in SP2bKD/EICD cells are shown. Cytokines increased in both the RNA-seq analysis and cytokine array are
indicated with red font. d The 427 cells were transiently transfected with the GFP gene under the UAS promoter, GAL4 DNA binding domain
(GAL4-DBD)-fused EICD, and tdTomato as a transfection marker. The degree of GFP expression in tdTomato-positive cells was analyzed using flow
cytometry. The degree of GFP expression in each condition is shown as a bar graph (n = 3). Error bars indicate SEM. e 427 cells were transfected
with GFP gene under CCL20 promoter, EICD, and FLAG-tagged EICD (or FLAG-tagged GAL4-DBD as a control), and tdTomato. The degree of GFP
expression of tdTomato positive cells in each condition was subtracted by that of empty vector-transfected cells followed by normalization
against that of 0.5 μg FLAG-EICD-transfected cells (left). Expression level of FLAG constructs are shown (right)
Cho et al. BMC Biology           (2020) 18:60 Page 9 of 16
Expression of epithin/PRSS14 and SPPL2B leads to the
reduced survival of patients with ER-negative breast
cancer
So far, this study indicates that the extracellular protease
epithin/PRSS14, upon its shedding and subsequent intra-
membrane proteolysis, can control intracellular transcrip-
tional events for enhanced cell motility and metastasis. To
investigate the clinical relevance of this finding, a bioinfor-
matics approach was utilized. Previously, we reported that
high expression of epithin/PRSS14 in patients with ER-
negative breast cancer indicated poor patient survival [12].
Consistently, we found that three out of four ER-negative
patient samples showed higher expression of epithin/
PRSS14 in tumor than in normal tissues (Additional file 1:
Figure S10). Interestingly, we also detected the band cor-
responding to the size of EICD in one patient (Additional
file 1: Figure S10, arrow). Considering the additional meta-
static potential resulting from EICD formation, it can be
assumed that the high expression of SPPL2b may consti-
tute an additional risk factor in patients that are ER-
negative. With this hypothesis, the relationship between
SPPL2b mRNA levels and the survival of patients with
breast cancer was analyzed using The Cancer Genome
Atlas data set. In patients that were ER-positive, the ex-
pression levels of SPPL2B (high or low, determined based
on the median expression level of SPPL2B among those
patients) did not show any correlation to the survival of
those patients (Fig. 6a). However, in patients with ER-
negative breast cancer, the SPPL2Bhigh group showed
poorer survival than the SPPL2Blow group (Fig. 6a) with
the hazard ratio calculated as 1.88 (p = 0.076), implying an
adverse effect of SPPL2B on the survival of patients with
risks from epithin/PRSS14. When the expression levels of
both SPPL2B and epithin/PRSS14 were considered in pa-
tients that were ER-negative, the epithin/
PRSS14highSPPL2Bhigh group showed the poorest survival
Fig. 6 The possible relationship between EICD generation and the prognosis of patients with breast cancer. a The Kaplan-Meier survival analysis
of four patients with breast cancer grouped by ER status and SPPL2B expression (hi, high; lo, low) is shown. b The Kaplan-Meier survival analysis
of patients that were ER-negative grouped by expression levels of epithin/PRSS14 and SPPL2B is shown. The p values were calculated using log-
rank statistics. *p < 0.05; **p < 0.01; ***p < 0.001. c A hypothetical model for EICD generation and dual functions of epithin/PRSS14 in metastasis
are illustrated
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pattern (Fig. 6b), suggesting the clinical significance of the
intramembrane proteolysis of epithin/PRSS14. This bio-
informatics analysis suggests that the high expression of
SPPL2B and epithin/PRSS14 in patients with ER-negative
breast cancer may worsen the symptoms, and thus, these
can be used as markers for poor prognosis in patients with
ER-negative breast cancer.
Discussion
This study demonstrates that the ectodomain shedding of
epithin/PRSS14 induces the SPPL2b-mediated intramem-
brane proteolysis of NTF, resulting in the release of EICD
from the plasma membrane. EICD, in turn, localizes in
the nucleus and induces transcriptional changes leading to
an increase in gene expression, which possibly enhances
cell motility and cancer metastasis (Fig. 6c). Therefore, the
shedding of epithin/PRSS14 in cancer cells can result in
bidirectional effects; extracellularly, the released protease
domain of epithin/PRSS14 can induce the proteolytic
modulation of extracellular environments, and intracellu-
larly, the liberated EICD can control gene expression.
The extracellular functions of epithin/PRSS14 have
been extensively studied. It has been shown to induce
matrix degradation directly through its own proteolytic
activity [37] or through the activation of other matrix-
degrading enzymes such as urokinase-type plasminogen
activators [38] and matrix metalloproteinase-3 [15].
Moreover, epithin/PRSS14 can proteolytically activate
growth factors/receptors, including protease-activated
receptor 2 [39, 40], hepatocyte growth factor [17], and
Tie2 [13], and thus modulate extracellular environments
favoring the migration and invasion of cancer or im-
mune cells. Because ectodomain shedding can release
most of the extracellular parts of epithin/PRSS14 from
the cell surface, it can extend the area affected by these
extracellular functions beyond the surface of the cell ex-
pressing the protease. Consistent with this, the intracel-
lular functions of epithin/PRSS14, revealed by the
current study, are also involved in the modulation of
extracellular environments. Intriguingly, most genes, of
which expressions are markedly increased by EICD, en-
code secretory molecules, such as matrix metalloprotein-
ases, cytokines, and growth factors (Fig. 5a), the primary
regulators of extracellular environments. In addition,
their functions are closely related to cell migration and
invasion. For example, CCL20, the expression/secretion
of which was most markedly increased by EICD in both
the RNA-seq (Fig. 5a) and protein arrays (Fig. 5b), is the
ligand of CC chemokine receptor 6 (CCR6) [41] of
which signaling has been demonstrated to induce the
epithelial-to-mesenchymal transition (EMT), migration,
invasion, tumorigenesis, and metastasis of various cancer
cells [42–46]. CXCL2, another major cytokine regulated
by the presence of EICD (Fig. 5a), is also well-known to
promote cancer progression [47] and metastasis [34].
Therefore, it seems that these characteristic bidirectional
functions of ectodomain shedding of epithin/PRSS14
can cooperatively facilitate metastasis; its intracellular
function can convert primary epithelial tumor cells into
migratory mesenchymal carcinoma cells, while its extra-
cellular function allows the degradation of the extracel-
lular matrix and makes a path for the invading cells.
At the moment, however, how EICD can induce tran-
scriptional activation is not currently known. Although
the expression of EICD alone sufficiently induced the ex-
pression of various genes in the RNA-seq analysis (Fig.
5a) and increased the promoter activity of CCL20 (Fig.
5e), EICD fused to the Gal4-DNA binding domain did
not stimulate the promoter activity of the UAS reporter
(Fig. 5d), showing that EICD itself does not contain
transactivation activity. Therefore, it seems that EICD
requires a cofactor(s) to induce specific gene expression
and it may control the activity of such cofactors. Pro-
moter analysis using the GeneCards database [48] on
genes whose expression increased in both the RNA-seq
analysis and cytokine antibody array (Fig. 5c, indicated
with red) revealed that several transcription factors, such
as IKZF1, POLR2A, CEBPB, MAX, and SP1, are com-
monly involved in their transcription, suggesting that
EICD may cooperate with these transcription factors to
induce genetic changes. In this regard, it would be an in-
triguing future study to investigate the possible cofactors
of EICD-mediated intracellular functions. Moreover, the
RIP of other type II transmembrane serine proteases [5]
and, if present, their differential regulation of gene ex-
pression and the mechanism underlying the specific gen-
etic control will be of interest in the future.
Conclusions
In conclusion, this study reveals that the intracellular
domain of epithin/PRSS14 can control gene expression
when released from the membrane upon ectodomain
shedding of its extracellular domain. This intracellular
function cooperates with the extracellular proteolytic
functions of the protease can increase cell motility and
result in enhanced metastasis. The unexpected function
of epithin/PRSS14 revealed by this study strongly sug-
gests that a possible epithin/PRSS14-targeted cancer
therapy [6] should consider not only its protease activity
but also the intracellular transcriptional function of
EICD in tumor progression. More generally, this sug-
gests that similar intramembrane proteolysis possibly oc-
curring in other membrane proteases, such as ADAM10
[49], and their not-yet-identified intracellular functions
should be considered when their proteolytic activities
are targeted in cancer treatment. Conceptionally, this
study also provides a unique example of bidirectional
transmembrane signaling in which extracellular
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functions of a membrane protein are systematically
aided by its simultaneous intracellular functions.
Methods
Plasmids
To generate FLAG-EICD and FLAG-epithin/PRSS14,
epithin/PRSS14 Met1 to Trp55 (EICD) or full length
was amplified by PCR and cloned into NotI and BamHI
sites of the p3XFLAG-CMV10 vector. For lentiviral in-
fection of EICD, 3XFLAG-EICD was also cloned into a
lentiviral vector, pRRLSIN.cPPT.PGK-IRES-GFP.WPRE,
modified from pRRLSIN.cPPT.PGK-GFP.WPRE (plas-
mid ID 12252; Addgene). Human SPPL2b cDNA was
purchased from OriGene. UAS-GFP reporter was gener-
ated by cloning EGFP cDNA into pHR_5x Gal4 UAS
vector (Addgene, #79119). CCL20-GFP reporter con-
structs were purchased from GeneCopoeia
(MPRM34109-LvPF02). cDNA encoding SPPL2b tagged
with C-terminal HA was generated by PCR. Epithin/
PRSS14 N-terminal end from Met1 to Ala44 fused with
GAL4-VP16, EICD-GAL4-VP16, were generated by PCR
and inserted into the pM vector (Clontech). The DNA
sequence corresponding to Lys45-Val855 of epithin/
PRSS14 was inserted into the 3′ of VP16 in the Epi (1-
44)-GAL4-VP16 construct, to generate full-length Epi-
GAL4-VP16. Epi-GAL4-VP16-strep construct was gen-
erated by cloning of PCR-amplified Epi-GAL4-VP16 into
pcDNA3.1 vector containing Strep coding sequence. For
transient knockdown of epithin/PRSS14, two epithin/
PRSS14-specific siRNAs, Epi-1 (target sequence:
GCTTGCTGGTGTGGCACTTCCATTA) and Epi-2
(target sequence: GGTGCGCTTCAAACTCTTC), and a
universal control siRNA (target sequence: TTCTCC
GAACGTCTCACG) were purchased from GenePharma.
Cell lines and antibodies
427, 427(epiKD), and 4T1KD cells were maintained as
described previously [13]. To generate 427(SP2bKD)-10
and -16 cells, shRNA against mouse SPPL2b (target se-
quence: CCGAGCAGCCTCCAAGTGA) cloned in pSU-
PER (Oligoengine) was transfected into 427 cells with
pcDNA3, selected for antibiotic (G418) resistance, and
single-cell clones derived from the antibiotic-resistant
pool were tested for their SPPL2b mRNA expression
using qPCR. To generate the 427(EICD) cell lines, the
intracellular domain of epithin/PRSS14, Met1-Trp55
(EICD) cloned in p3XFLAG-CMV10 vector, p3XFLAG-
CMV10/EICD was transfected into 427 cells, selected for
antibiotic resistance, and single-cell clones stably ex-
pressing EICD were examined by Western blot using the
anti-FLAG antibody. Anti-epithin/PRSS14 antibodies,
anti-N (against intracellular domain) (WB, 1:500; ICC, 1:
100), anti-C (against extracellular domain) (ICC, 1:100),
and mAb5 (WB, 1:200), were previously described [18].
Anti-matriptase antibody (IM1014, Milipore, RRID:AB_
2255240) (WB, 1:1000), anti-FLAG antibody (clone M2,
F1804, Sigma, RRID:AB_262044) (WB, 1:1000; ICC, 1:
200), anti-HA antibody (Y-11, sc-805, Santa Cruz Bio-
technology, RRID:AB_631618) (WB, 1:1000; ICC, 1:100),
anti-Strep antibody (2-1507-001, IBA, RRID:AB_
513133), and anti-β-tubulin antibody (T4026, Sigma,
RRID:AB_477577) (WB, 1:1000) were purchased. Anti-
hN antibody against intracellular domain of human
epithin/PRSS14 was raised in rabbits injected with hu-
man epithin/PRSS14 peptide (Gly2-His26) and further
purified by affinity to recombinant protein, 6xHis-tagged
intracellular domain of human epithin/PRSS14.
Immunocytochemistry
Cells grown on gelatin-coated slide covers were fixed
with 3.7% paraformaldehyde in PBS for 10 min, perme-
abilized with 0.1% TritonX-100 in PBS (PBS-T) for 30
min, and incubated in blocking solution (10% goat
serum, 1% gelatin, and 0.1% TritonX-100 in PBS) for 30
min. After washing with PBS-T, samples were treated
with a primary antibody in blocking solution for 1 h.
Cells then were washed with PBS-T and incubated with
FITC-conjugated secondary antibodies (Jackson Immu-
noResearch, 711-095-152, 715-095-150, 711-025-152,
and 715-025-150) for 50 min. The coverslips were
mounted with DAPI (VECTASHIELD, H-1500) and ob-
served under the fluorescence microscope (Axioplan200
M, Carl Zeiss). Images were processed in Photoshop
CS6 (Adobe). For quantification of nuclear dots stained
by anti-N antibody, a threshold level was set as 1.5 times
the mean fluorescence of pixels of which intensities are
less than top 60% fluorescence intensity of each nuclear
region. If the mean fluorescence of a particular pixel and
the 8 pixels surrounding it in the nuclear image is
greater than the threshold, the pixel was considered as
an EICD-positive pixel. The sum of the fluorescence in-
tensity of EICD-positive pixels in each cell divided by
the mean fluorescence of nuclear region of the cell was
calculated and represented as normalized EICD nuclear
localization. This procedure was automatically per-
formed by a custom Matlab code.
Cell-based luciferase reporter assay
To examine the liberation of the intracellular domain of
epithin/PRSS14, 427 cells were transfected with Epi (1-
44)-GAL4-VP16, Epi-GAL4-VP16, or empty vector with
GAL4-UAS-Luciferase and pCMV-β-galactosidase (Pro-
mega). At 24 h after transfection, these cells were starved
for serum and stimulated with PMA/serum and/or ecotin.
Cells were lysed, and the luciferase assay was performed
according to the manufacturer’s instructions (Promega).
Luciferase and β-galactosidase activities were measured
using a MicroLumat Plus LB 96 V (Berthold technologies),
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and the luciferase activity was normalized by β-
galactosidase activity.
Biochemical detection of epithin/PRSS14 fragments
Serum starved 427 cells on a 100-mm dish were treated
with 20 μM TAPI-0 (Calbiochem, 579050) for 2 h, DAPT
(Sigma, 565770) for 16 h, or (Z-LL)2ketone (Calbiochem,
421050) for 16 h. Then, cells were further incubated with
1 μM PMA (Sigma, P1585) for additional 2 h. Whole
media were harvested and concentrated using
trichloroacetic acid and analyzed for Epi-S′, as described
previously [21]. Ice-cold PBS washed cells were lysed
with lysis buffer (50 mM HEPES (pH 7.4), 150 mM NaCl,
1% NP-40, 0.5% Sodium deoxycholate, and 1 mM EDTA
in the presence of protease inhibitors, leupeptin, aproti-
nin, and pepstatin. The immunoprecipitation of the
PRSS14 N-terminus was performed by antibodies and
protein A-Sepharose bead mixtures for 2 h, at 4 °C. The
immunoprecipitates were analyzed by SDS-PAGE using
4–12% NuPAGE gradient gel (Invitrogen), followed by
Western blot. For the competition assay, 300 ng of N
peptide 12GSQDFGAGLKYNSR25 was pre-incubated
with anti-N antibody.
Subcellular fractionation assay
Cells were incubated with serum-free media for 2 h and
treated 1 μM PMA for additional 2 h. Those cells were
harvested in a lysis buffer for subcellular fractionation
(50 mM Tris-HCl, pH 7.5, 10 mM NaCl, 1 mM MgCl2, 2
mM EDTA, and protease inhibitors) and passed through
a 26-G needle on ice. The nuclear pellets were collected
after centrifuge at 700g for 10 min at 4 °C. The superna-
tants were centrifuged at 10,000g for 10 min to discard
contamination of nuclear fraction and re-centrifuged at
100,000g for additional 1 h. The supernatants were col-
lected as cytosolic fraction. The nuclear pellets were re-
suspended with nuclear lysis buffer (50 mM Tris-HCl,
pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxy-
cholate, and protease inhibitors), incubated for 1 h on
rotator at 4 °C, and clarified by centrifugation at 17,000g
for 20 min. Resulting cytosolic and nuclear fractions
were analyzed by Western blot.
Wound healing and invasion assays
For the wound healing assays, cell monolayers main-
tained in a serum-free medium were scratched using a
P200 pipet tip. Cells were washed to remove cell debris
and incubated in 1% serum-containing medium for 24 h.
Photographs were taken at 0 and 24 h after wounding
using Axiovert 200M, and the area covered by migrating
cells was determined by the ratio of the scratch area at
0 h to the scratch area at 24 h using ImageJ Software.
The invasion assay was performed using a BioCoat
Matrigel Invasion Chamber (Corning, 354,480)
according to the manufacturer’s instructions. The 3 ×
105 cells in the serum-free medium were added into the
upper chamber. The lower chamber was filled with
DMEM containing 2% serum with or without 1 μM
PMA. After 24 h of incubation, the cells on the upper
surface of the membrane were removed using cotton
swabs. The invaded cells on the lower surface of the
membrane were fixed with 100% methanol for 10 min
and stained with 0.2% crystal violet for 5 min. The in-
vaded cells were counted under Axioimager M1, and 15
fields were counted. The total number of cells was di-
vided by the number of counted fields in each assay.
Metastasis assay
4T1KD cells and 4T1KD/EICD:GFP cells were mixed at
approximately 7:3 ratio and analyzed by flow cytometry
to confirm the ratio. Approximately 5 × 105 cells from
the mixture in 100 μl PBS were injected into the tail vein
of 5-week-old BALB/c mice (n = 5). Three weeks after
injection, all mice were sacrificed by cervical dislocation
and their lungs were removed and frozen. Each lung
tumor nodules from the mice were lysed with RIPA buf-
fer and analyzed for EICD expression using western blot.
RNA-sequencing and data analysis
FLAG-EICD was co-transfected with pEGFP-c1 (Clon-
tech) into SP2bKD-10 cells. At 24 h after transfection,
GFP-positive cells were sorted using FACSAria II (BD
Bioscience). The collected GFP-positive cells were im-
mediately lysed with TRIzol (Thermo Fisher Scientific,
15596026), and RNA was extracted. The quality of ex-
tracted RNA was verified using an Agilent 2100 BioAna-
lyzer. RNA-seq was performed at TheragenEtex Bio
Institute (Suwon, Korea) using Illumina HiSeq 2500
paired-end RNA sequencing. Reads were aligned with
Tophat (v2.1.1) [50], and Fragments per kilobase of exon
per million reads (FPKMs) were calculated using Cuf-
flinks (v2.1.1) [51]. Cuffdiff (v2.1.1) [52] was used for
normalization. Before generating the MA plot, 0.001 was
added to the FPKM values of the EICD-transfected sam-
ple and genes with FPKM values less than 0.01 were dis-
carded. For ontology analysis of the EICD-induced gene
set, the DAVID functional annotation tool [53, 54] and
REVIGO [55] were used.
Cytokine array
SP2bKD-10 or SP2KD/EICD cells were incubated with
0.5% serum containing DMEM for 24 h. Then, condi-
tioned medium (CM) were concentrated 10 times by cen-
trifugation at 4000 rpm for at 4 °C using ultrafiltration
units (Amicon Ultra-15 Centrifugal Filter Unit, 3 kDa cut-
off, Millipore). The concentrated CMs were analyzed to
determine the expression levels of secreted cytokines by
Proteome Profiler Mouse XL Cytokine Array (R&D
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Systems), according to the manufacturer’s instructions.
The signals were detected by ImageQuant LAS 4000 Mini
(GE Healthcare), and the pixel density was analyzed by
imageJ software.
Data analyses using TCGA
TCGA data were downloaded using the Broad Institute’s
Firehose, a web portal site that has been developed aim-
ing to deliver automated analyses of the TCGA data to
general users. For expression correlation analysis, ex-
pression values of all patients were drawn in scatter plots
with linear interpolation curves between the two genes.
The correlation coefficient r values between two genes
were calculated using the Pearson correlation, and un-
paired two-tailed Student’s t test was performed. For the
5 years survival rate, Kaplan-Meier survival analysis was
used using TCGA breast cancer data excluded data
whose contacts were lost in 5 years. The p values were
calculated using a log-rank (Mantel-Cox) test, and the
hazard ratio (HR) was determined by the Mantel-
Haenszel method.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12915-020-00787-3.
Additional file 1: Figure S1. Surface localization of Epi-GV fusion pro-
tein. (A) Diagram of Epi-GV construct with C-terminal Strep tag (Epi-GV-
strep). (B) Epi-GV-strep construct (or MOCK) was transfected to 293F cells
with a trace amount of EGFP cDNA as a transfection marker, and its sur-
face expression was analyzed by flow cytometry. Representative dot plots
are shown. Figure S2. PMA-induced nuclear localization of epithin/
PRSS14 intracellular domain. (A) 427 cells were transfected with two siR-
NAs against epithin/PRSS14, starved for serum, and stimulated with PMA
or not. Cells were then stained with anti-N antibody (green) and DAPI
(blue). Representative images are shown. Scale bars, 20 μm. (B) The com-
putational method for determining EICD-positive pixels is illustrated. If
the mean fluorescence of a particular pixel and the 8 pixels surrounding
it in the nuclear image is greater than the threshold described in
Methods section, the pixel was considered as an EICD-positive pixel. (C)
Representative anti-N antibody-stained original image and binary image
with epithin/PRSS14 positive pixels indicated in white are shown. (D) In
the experiment described in A, normalized EICD nuclear localization (the
sum of the fluorescence intensity of EICD-positive pixels in each cell di-
vided by the mean fluorescence of nuclear region of the cell) was calcu-
lated and represented as bar graph. At least 57 cells from three
microscopic fields were used for each condition. The error bar indicates
SEM. ****p < 0.0001 (unpaired two-tailed Student’s t test). Figure S3.
Localization of EICD in the nuclear fraction. (A) 427 cells transfected with
specific siRNAs for epithin/PRSS14 and stimulated with PMA as in Fig. 2b.
EICD in each condition was detected by immunoprecipitation and subse-
quent Western blot. CS, control serum. (B) 427 cells were prepared as in
(A), the presence of EICD in cytosolic and nuclear fractions was deter-
mined by western blot using anti-N antibody. Arrowhead and arrow indi-
cate NTF and EICD, respectively. GAPDH (empty arrowhead) and Histone
H3 (asterisk) were used for cytosolic and nuclear marker, respectively.
Media and whole cell lysate were also analyzed for epithin/PRSS14 ex-
pression using mAb5 with tubulin expression as an internal loading con-
trol. Figure S4. Effects of γ-secretase inhibitor and SPPL family inhibitor
on intramembrane proteolysis of epithin/PRSS14. The 427 cells were
treated with indicated concentration of DAPT or (Z-LL)2ketone for 16 h,
and the spontaneous EICD generation was detected by immunoprecipi-
tation and Western blot using anti-N antibody. Arrowhead and arrow
indicate NTF and EICD, respectively. Figure S5. Reduced nuclear
localization of EICD in SPPL2b-knockdown cell lines. (A) EICD nuclear
localization in 427 wild type and SP2bKD-10 cells shown in Fig. 3g was
quantified as Figure S2D. At least 73 cells from three microscopic fields
were used for each cell type. The error bar indicates SEM. ****p < 0.0001
(unpaired two-tailed Student’s t test). (B) The localization of EICD in cyto-
solic and nuclear fraction of SP2bKD cells was analyzed as in S3B. Arrow-
head and arrow indicate NTF and EICD, respectively. GAPDH (empty
arrowhead) and Histone H3 (asterisk) were used for cytosolic and nuclear
marker, respectively. Figure S6. Epithin/PRSS14 and EICD-dependent cell
motility. (A) 427 cells were transfected with siRNAs against epithin/
PRSS14, and their wound healing migration was tested as in Fig. 4a. Data
are presented as the means of the recovered area (six fields per each cell
type, n = 3). (B) 427 cells were transfected with siRNAs against epithin/
PRSS14, and their invasion through Matrigel-coated pores of the transwell
chamber was analyzed as in Fig. 4b. Numbers of invaded cells to the
other side of the chamber for 24 h were counted, normalized against that
of 427 cells, and shown as bar graphs (five fields per each cell type, n =
3). (C) Wound healing migration of 427, SP2bKD-10, and EICD-transfected
SP2bKD-10 cells was analyzed as in (A). Data are presented as the means
of the recovered area (six fields per each cell type, n = 3). (D) Transwell in-
vasion of 427, SP2bKD-10, and EICD-transfected SP2bKD-10 cells was ana-
lyzed as in (B). Numbers of invaded cells to the other side of the
chamber for 24 h were counted, normalized against that of 427 cells, and
shown as bar graphs (five fields per each cell type, n = 3). Error bars indi-
cate SEM in all panels. p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
(unpaired two-tailed Student’s t test). Figure S7. Western blot analysis of
tumor nodules. (A) Twenty tumor nodules from each lung of five mice
injected with 4 T1 and 4T1KD/EICD:GFP mixture were isolated, lysed, and
analyzed by Western blot to detect GFP expression. Western blot using
anti-tubulin antibodies were used as loading controls in the same blot.
GFP-positive nodules are indicated with red font. (B) In case GFP expres-
sion was not evident due to the small size of the nodules and the subse-
quent low protein concentration in the sample, e.g., lanes 2, 15, 17 from
mouse #4, the Western blot was repeated using negative (4T1KD) and
positive control cells (4T1KD/EICD:GFP). Figure S8. Ontology analysis of
the EICD-induced gene set. The gene ontology (GO) of total 233 DEGs
with more than two-fold increases in EICD-transfected cells was analyzed
as in methods. The top ten ranked GO terms were indicated with
-log(p value). Figure S9. Cytokine array. Positions of various cytokine
antibodies spotted in the array are shown. Figure S10. EICD in human
breast cancer patients. The normal (N) and tumor (T) tissues from four ER-
negative breast cancer patients were lysed and analyzed by Western blot
with anti-human C-terminal (IM1014) and anti-human N antibodies.
Arrowhead and arrow indicate NTF and EICD, respectively.
Additional file 2: Table S1. Differentially expressed genes (DEG) in the
control and EICD-transfected cells. DEGs with p values less than 0.05 from
the RNA-seq analysis are listed with gene information, FPKMs in the con-
trol and EICD-transfected cells, the binary logarithm of the ratio (M), and
the geometric mean (A).
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